The state of innovation in drug development

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 2, 2008, Pages 227-230

  Kola, I ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SITAGLIPTIN;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL DECISION MAKING; DIABETES MELLITUS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; MOLECULAR IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; BIOMEDICAL RESEARCH; DIFFUSION OF INNOVATION; DRUG APPROVAL; DRUG COSTS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; LEGISLATION, DRUG; RESEARCH SUPPORT AS TOPIC; TECHNOLOGY, PHARMACEUTICAL;

EID: 38349090575     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100479     Document Type: Review

References (11)

1. Owens, J. 2006 drug approvals: finding the niche. Nat. Rev. Drug Discov. 6, 99-101 (2007).
2. Mullin, R. Drug development costs about $1.7 billion. Chem. Eng. News 81, 8 (2003).
3. US Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products 〈http://www.fda. gov/oc/initiatives/criticalpath/whitepaper.html〉 (2004).
4. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
5. Elias, T., Gordian, M., Singh, N. & Zemmel, R. Why products fail in phase III. In Vivo 24, 49-54 (2006).
6. Kola, I. & Hazuda, D. Innovation and greater success in drug discovery and development: from targets to biomarkers. Curr. Opin. Biotechnol. 16, 644-646 (2005).
7. van't Veer, L.J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
8. Kola, I. Pharmacogenetics: where are we and where are we heading? Pharmacogenomics 6, 793-795 (2005).
9. Boorsook, D., Becerra, L. & Hargreaves, R. A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug. Discov. 5, 411-424 (2006).
10. Herman, G.A. et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91, 4612-4619 (2006).
11. The bitterest pill. Nature 444, 532-533 (2006).